|
Originally published In Press as doi:10.1074/jbc.M108594200 on September 17, 2001
J. Biol. Chem., Vol. 276, Issue 47, 43748-43755, November 23, 2001
Excessive Hexosamines Block the Neuroprotective Effect of
Insulin and Induce Apoptosis in Retinal Neurons*
Makoto
Nakamura ,
Alistair J.
Barber ,
David A.
Antonetti §,
Kathryn F.
LaNoue§,
Katherine A.
Robinson¶,
Maria G.
Buse¶, and
Thomas W.
Gardner §
From the Pennsylvania State Retina Research Group, The Ulerich
Ophthalmology Research Center, the Departments of
Ophthalmology and § Cellular and Molecular
Physiology, Pennsylvania State University College of Medicine,
Hershey, Pennsylvania 17033 and ¶ Division of Endocrinology,
Diabetes and Medical Genetics, Department of Medicine, Medical
University of South Carolina, Charleston, South Carolina 29425
Received for publication, September 6, 2001
 |
ABSTRACT |
In addition to microvascular
abnormalities, neuronal apoptosis occurs early in diabetic retinopathy,
but the mechanism is unknown. Insulin may act as a neurotrophic factor
in the retina via the phosphoinositide 3-kinase/Akt pathway. Excessive
glucose flux through the hexosamine biosynthetic pathway (HBP) is
implicated in the development of insulin resistance in peripheral
tissues and diabetic complications such as nephropathy. We tested
whether increased glucose flux through the HBP perturbs insulin action and induces apoptosis in retinal neuronal cells. Exposure of R28 cells,
a model of retinal neurons, to 20 mM glucose for
24 h attenuated the ability of 10 nM insulin to rescue
them from serum deprivation-induced apoptosis and to phosphorylate Akt
compared with 5 mM glucose. Glucosamine not only impaired
the neuroprotective effect of insulin but also induced apoptosis in R28
cells in a dose-dependent fashion. UDP-N-acetylhexosamines (UDP-HexNAc), end products of the
HBP, were increased ~2- and 15-fold after a 24-h incubation in 20 mM glucose and 1.5 mM glucosamine,
respectively. Azaserine, a glutamine:fructose-6-phosphate amidotransferase inhibitor, reversed the effect of 20 mM
glucose, but not that of 1.5 mM glucosamine, on attenuation
of the ability of insulin to promote cell survival and phosphorylate
Akt as well as accumulation of UDP-HexNAc. Glucosamine also impaired
insulin receptor processing in a dose-dependent manner but
did not decrease ATP content. By contrast, in L6 muscle cells,
glucosamine impaired insulin receptor processing but did not induce
apoptosis. These results suggest that the excessive glucose flux
through the HBP may direct retinal neurons to undergo apoptosis in a
bimodal fashion; i.e. via perturbation of the
neuroprotective effect of insulin mediated by Akt and via induction of
apoptosis possibly by altered glycosylation of proteins. The HBP may be
involved in retinal neurodegeneration in diabetes.
 |
INTRODUCTION |
Diabetic retinopathy
(DR)1 is usually considered a
disease of the microvasculature, but significant involvement of
neuronal components has been implicated as well. Previous studies by us and others (1, 2) indicate that neuronal cells in the retina, including
ganglion cells, undergo apoptosis both in rats and humans with early
diabetes. The pro-apoptotic BAX protein was also reported to be induced
in neuronal as well as vascular components of the retina in patients
with diabetes (3). However, the mechanism of the neurodegeneration in
DR remains open to debate. Because insulin administration reduced the
rate of apoptosis in streptozotocin-diabetic rats (2), systemic
metabolic compromise such as hyperglycemia or defective insulin action,
or both, adversely affects neuronal survival in the retina.
Insulin is known to act as a neurotrophic factor in cultured neuronal
cells including retinal ganglion cells (4, 5). Insulin exerts a broad
array of biological responses by binding to its specific receptors and
activating the intracellular signaling cascades such as the
IRS-1/PI3K/Akt pathway. Our recent findings have indicated that
physiological concentrations of insulin rescue R28 cells, a model of
retinal neurons (6-8), from apoptosis induced by serum withdrawal by
activating the PI3K/Akt pathway, while inactivating caspase-3 (9). The
neuronal components in the retina express abundant IR (10, 11). These
observations suggest that insulin may play a critical role in
maintaining neuronal survival in the retina.
Increased glucose flux through the HBP is thought to play a role in
glucose-induced insulin desensitization in peripheral tissues and the
development of diabetic complications such as nephropathy (12-26). The
first and rate-limiting enzyme in this pathway, GFAT, catalyzes the
conversion of fructose 6-phosphate to glucosamine 6-phosphate. The
latter is rapidly metabolized to UDP-HexNAc, i.e.
UDP-N-acetylglucosamine and
UDP-N-acetylgalactosamine, in an ~3:1 ratio.
Although only up to 3% of glucose taken up by cells enters into the
HBP, the end products UDP-HexNAc serve as essential substrates for the
synthesis of glycosyl side chains of proteins and lipids (12-14).
Thus, even modest perturbations of the amount of glucose flux through
the HBP can exert diverse effects on protein functions. Glucosamine
enters this pathway distal to GFAT (27) and induces insulin resistance
in muscles and adipocytes (15-20). Increased ambient glucose
concentration or exposure to glucosamine impairs insulin stimulation of
Akt activity in fat cells (18), muscle (22, 23), liver (24), and rat-1
fibroblasts (28). On the other hand, the HBP has also been linked to
glucose-mediated changes in cellular growth and growth factor
expression. For example, high glucose stimulates transforming growth
factor- mRNA levels and extracellular matrix synthesis via the
HBP in mesangial cells (25, 26), which is presumably associated with
the development of diabetic nephropathy.
Under physiological conditions, endothelial and glial cells elegantly
regulate glucose supply to the neuronal cells in the retina (29).
However, DR adversely affects both glial and endothelial functions even
at the early stages of DR (30-33). Intracellular concentrations of
glucose are elevated in diabetic retinal tissues (34, 35). Thus,
glucose metabolism in retinal neurons is likely to be perturbed under
diabetic conditions. The retina expresses active GFAT (36) and
synthesizes UDP-HexNAc (37). Hexosamine content is increased in retinal
tissues in humans and rats with diabetes (38) and in the vitreous in
alloxan-induced diabetic rabbits (39).
From the evidence presented above, we hypothesized that excessive
glucose flux through the HBP and accumulation of UDP-HexNAc could
reduce the neuroprotective effect of insulin or directly affect
survival mechanisms in retinal neurons. To test this hypothesis, we
investigated the effects of high glucose and glucosamine on insulin-mediated anti-apoptosis and IR processing and signaling in R28
cells. Our results indicate that high glucose and glucosamine prevent
insulin from protecting R28 cells from apoptosis, which is associated
with reduced insulin stimulation of Akt activity. Furthermore, at
higher concentrations glucosamine induces apoptosis even in serum-fed
R28 cells.
 |
EXPERIMENTAL PROCEDURES |
Materials and Reagents--
Azaserine, bovine insulin,
glucosamine, and mannitol were purchased from Sigma. All other dry
chemicals were purchased from Fisher unless otherwise stated.
Trans35S-label metabolic labeling reagents were from ICN
Biomedicals (specific activity >1000 Ci/ml; 10 mCi/ml). DMEM with 1000 mg/liter glucose and methionine-free minimal essential medium were
purchased from Sigma. Rabbit polyclonal anti-IR (N-20) and -
(C-19) subunit antibodies were purchased from Santa Cruz Biotechnology.
Anti-phospho-Ser473 and total Akt antibodies were from Cell
Signaling Technology.
Cell Culture--
R28 cells were a generous gift from Dr. Gail
M. Seigel, State University of New York, Buffalo (7-11). They were
grown in DMEM containing 5 mM glucose supplemented with
10% newborn bovine serum (Flow Laboratories) and differentiated to
neurons on laminin-coated plates or coverslips with addition of
cell-permeable cAMP (Sigma) 24 h prior to the following
experiments, as described previously (9). L6 muscle cells (40) were
purchased from ATCC and also cultured in DMEM supplemented with 10%
newborn bovine serum.
Apoptosis Quantification--
R28 and L6 cells seeded at a
density of 2 × 105/cm2 on coverslips were
incubated as described above. The media were replaced with DMEM
containing the indicated concentrations of glucose, mannitol, and
glucosamine for 24 h with or without 0.1 µM
azaserine. The cells were maintained in serum, deprived of serum, or
deprived of serum and treated with 10 nM insulin for an
additional 24 h. The cells were fixed in 1% paraformaldehyde and
then incubated with a rabbit polyclonal antibody against activated
caspase-3 (1:1000; CM-1, Idun Pharmaceuticals). The secondary antibody
was rhodamine red-X-conjugated donkey anti-rabbit (1:2000, Jackson ImmunoResearch). Cells were counter-stained with bisbenzimide Hoechst
33258 (0.5 µg/ml; Sigma) (9). Five visual fields under fluorescence
microscope were randomly sampled from each coverslip, and all the cells
stained with Hoechst dye in each field were counted. The number of
pyknotic cells with condensed or fragmented nuclei was summated in the
five sampled regions. The percentage of pyknotic cells per coverslip
was then calculated as described (9). In parallel, the percentage of
CM-1 immunoreactive cells per coverslip was also measured.
UDP-HexNAc Assay--
UDP-HexNAc, the end product of the HBP,
was measured as described previously (20, 41). After a 24-h incubation
in 5 mM glucose, 20 mM glucose, or 5 mM glucose plus 1.5 mM glucosamine, with or
without 10 nM insulin or 0.1 µM azaserine,
100-mm plates of R28 cells were washed once with ice-cold
phosphate-buffered saline and homogenized in 0.5 ml of 0.3 M perchloric acid. The precipitates were pelleted by
centrifugation (5 min, 10,000 × g, 4 °C), and
perchloric acid was extracted from the supernatants with 2 volumes of
1:4 trioctylamine:1,1,2-trichlorofluoroethane (Sigma). The aqueous
phase was stored at 80 °C and analyzed within 5 days.
Nucleotide-linked hexoses and hexosamines were separated and measured
by anion exchange high pressure liquid chromatography. UDP-HexNAc and
UDP-hexoses were quantified by ultraviolet absorption (A254) and compared with external standards.
Immunoprecipitation and Immunoblotting--
Subconfluent R28 and
L6 cells plated on 60-mm dishes at a density of 4 × 105/cm2 were exposed to the indicated
concentrations of glucose, mannitol, and glucosamine for 24 h. The
cells were deprived of serum for 2 h prior to stimulation with 10 nM insulin for 5 or 30 min and then solubilized in
immunoprecipitation buffer (50 mM HEPES, pH 7.3, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 2 mM
Na3VO4, 10 mM sodium pyrophosphate,
10 mM NaF, 2 mM EDTA, 2 mM
phenylmethylsulfonyl fluoride, 10 mM benzamidine, 10%
glycerol, 1% Nonidet P-40, and 1 protease inhibitor tablet/10 ml).
Protein concentrations were determined with Pierce BCA reagent against
bovine serum albumin standard. Tyrosine phosphorylation of IR and
IRS-1 was determined by immunoprecipitation followed by phosphotyrosine
blotting as described previously (9, 33). Whole cell lysates (50 µg) were separated with either 7.5 or 10% SDS-PAGE, transferred, and probed with anti-IR or phospho-specific or total Akt antibodies (9).
Densitometric analysis of enhanced chemofluorescence
(Amersham Pharmacia Biotech) immunoblots was performed with ImageQuant
(Molecular Dynamics) and ECL immunoblots with NIH Image as described
previously (9, 33).
Pulse-Chase Metabolic Labeling--
Subconfluent R28
cells seeded on laminin-coated 100-mm plates were incubated in DMEM
containing 5 mM glucose and either 15 mM
mannitol or 15 mM glucosamine for 8 h. The plates were
washed twice and incubated for 1 h in pre-warmed methionine-free
minimal essential medium containing 5 mM glucose plus 15 mM mannitol or glucosamine supplemented with 10% dialyzed
fetal bovine serum (HyClone) and 25 mM HEPES, pH 7.4. The
media were exchanged for 2 ml containing 0.2 mCi/ml
[35S]methionine. Following incubation at 37 °C for 30 min, the cells were washed and chased for the indicated periods in
pre-warmed DMEM plus 10% newborn bovine serum containing 0.2 mM methionine and either 15 mM mannitol or
glucosamine. The cells were solubilized in 1 ml of lysis buffer (50 mM HEPES, pH 7.4, 137 mM NaCl, 2 mM EDTA, 100 µM phenylmethylsulfonyl fluoride, 1% Triton
X-100, 10 mM benzamidine, 1 protease inhibitor tablet/10
ml). Following a 15-min incubation at 4 °C and centrifugation, the
supernatant was absorbed for 60 min with 60 µl of protein
A-Sepharose. The cleared supernatant was incubated overnight with
anti-IR antibody at 4 °C. The immune complexes were incubated
with protein A-Sepharose for 2 h. The pellets were washed three
times with 1 ml of 50 mM HEPES, pH 7.4, 137 mM
NaCl, 0.1% Triton X-100, 100 µM phenylmethylsulfonyl fluoride, 0.1% SDS, 1 protease inhibitor tablet/10 ml and then boiled
in Laemmli's sample buffer. Proteins were separated by 7.5% SDS-PAGE.
Gels were treated with EN3HANCE (PerkinElmer Life Sciences), dried, and
subjected to fluorography.
ATP Assay--
After a 24-h incubation in 5 mM
glucose, 20 mM glucose, or 5 mM glucose plus
1.5 mM glucosamine, with or without 10 nM
insulin, 100-mm plates of R28 cells were washed three times with
ice-cold phosphate-buffered saline and collected with and sonicated in 0.5 ml of 2% perchloric acid. Following centrifugation (10,000 × g, 2 min, 4 °C), supernatants were neutralized to pH 7.0 with appropriate amounts of 3 M KOH, 0.5 M
MOPS, 0.1 M EDTA. To 200 µl of the neutralized cell
extract solution, 753 µl of 50 mM HEPES buffer, pH 7.4, containing 10 mM MgCl2 and 5 mM
EDTA, 20 µl of 45 mg/ml glucose, 20 µl of 25 mg/ml NADP, 2 µl of
glucose-6-P dehydrogenase ( 2.3 units) were added. Following
the stabilization of the absorbance at 340 nm, 5 µl of 1:5 diluted
hexokinase ( 1.1 units) was added. NADPH, which was generated as a
product stoichiometric with ATP, was measured before and after the
addition of hexokinase using a Beckman U640 spectrophotometer with
analytical wavelength of 340 nm (42). Duplicates were done for each
sample, blank, and standard curve measurement. ATP contents were
corrected for protein amount in the sample and expressed as nmol/mg protein.
Statistical Analysis--
Statistical comparisons were performed
by one-way analysis of variance with post hoc Student-Neuman-Keuls
multiple comparisons test or by two-tailed unpaired Student's
t test (Instat 2.0, Graphpad Software) (9). Statistical
significance was accepted if p < 0.05.
 |
RESULTS |
High Glucose and Glucosamine Inhibit the Anti-apoptotic Effect of
Insulin on R28 Cells--
We have demonstrated previously that insulin
can rescue differentiated R28 cells from apoptosis induced by serum
withdrawal in a dose-dependent fashion with a maximum
effect at 10 nM (9). To test whether high glucose or
glucosamine abrogates the rescue effect of insulin, R28 cells were
incubated for 24 h in DMEM plus serum containing 5 mM
glucose, 20 mM glucose, or increasing concentrations of
glucosamine with mannitol as an osmotic control. The cells were then
maintained in serum or deprived of serum with or without 10 nM insulin for an additional 24 h. Following the
Hoechst staining, the percentage of pyknotic cells in five randomly
sampled visual fields per coverslip (n = 3) was
calculated (Fig. 1). In the presence of
serum, less than 1% of cells incubated in 5 mM glucose
were pyknotic, whereas serum starvation led to pyknosis in ~15% of cells. Insulin treatment significantly (p < 0.01)
reduced the number of pyknotic cells to about 8%, which is consistent
with our previous observation (9). Exposure to 15 mM
mannitol did not show any effects on serum withdrawal-induced apoptosis
and insulin rescue of R28 cells. Cells exposed to 20 mM
glucose also had very few pyknotic nuclei in the presence of serum,
whereas serum deprivation gave rise to pyknosis to a similar degree as controls. However, insulin treatment did not decrease the number of
pyknotic cells, suggesting that high glucose had no deleterious effect
on cell survival but blocked the ability of insulin to rescue R28 cells
from apoptosis. In contrast, glucosamine induced apoptosis even in the
presence of serum and augmented the apoptosis induced by serum
deprivation in a dose-dependent fashion (Fig. 1). Thus, the
total population at counting was substantially less in cells treated
with 15 mM glucosamine as compared with other medium
conditions (Fig. 1A). 1.5 mM glucosamine
attenuated the anti-apoptotic effect of insulin to similar a degree as
20 mM glucose, whereas 15 mM glucosamine
completely abrogated that effect (Fig. 1B).

View larger version (83K):
[in this window]
[in a new window]
|
Fig. 1.
High glucose and glucosamine block the
anti-apoptotic effect of insulin on R28 cells. R28 cells on
laminin-coated coverslips were incubated in the indicated combinations
of glucose, mannitol, and glucosamine for 24 h and then left
untreated or deprived of serum with or without 10 nM
insulin for an additional 24 h. Following Hoechst 33258 staining,
the percentage of pyknotic cells (arrows) per coverslip was
calculated. A, a representative picture. Bar
indicates 50 µm. B, data represent the mean ± S.E.
of five randomly sampled visual fields in n = 3 coverslips. The experiments were repeated three times with reproducible
results. Insulin rescued R28 cells incubated in 5 mM
glucose or 5 mM glucose plus 15 mM mannitol
from apoptosis induced by serum withdrawal. Exposure to 20 mM glucose attenuated this neuroprotective effect of
insulin. Glucosamine treatment induces apoptosis even in the presence
of serum and abrogates the insulin rescue effect in a
dose-dependent fashion. * and indicate
p < 0.05 and p < 0.01 versus cells incubated in 5 mM glucose in
corresponding serum and insulin treatment conditions,
respectively.
|
|
Azaserine Reverses the Inhibitory Effect of High Glucose on
Insulin-mediated Neuroprotection--
To test whether the increased
flux of glucose through the HBP is involved in the attenuated rescue
effect of insulin in cells exposed to high glucose, the effect of
azaserine, a GFAT inhibitor (12), was investigated. Following the 24-h
incubation in the indicated media conditions with or without 0.1 µM azaserine, apoptosis was induced, and the
neuroprotective effect of insulin was determined as described above. In
addition to the Hoechst staining, immunocytochemistry using CM-1, an
antibody specifically recognizing activated caspase-3, was also
conducted (9). The ability of insulin to reduce apoptosis was expressed
as a ratio of percent pyknosis in cells deprived of serum to that in
cells deprived of serum and treated with insulin (Fig.
2B). In cells incubated in
media containing 5 mM glucose and 5 mM glucose
plus 15 mM mannitol, insulin increased cell survival approximately by 3-fold irrespective of the presence or absence of
azaserine. Incubation in 20 mM glucose again abrogated the neuroprotective effect of insulin in cells deprived of serum, whereas
in the presence of azaserine, 20 mM glucose no longer blocked the rescue effect of insulin (Fig. 2, A and
B). Thus, the HBP was, at least in part, involved in the
inhibitory effect of high glucose on insulin-mediated anti-apoptosis.
Consistent with this hypothesis, in cells exposed to 1.5 mM
glucosamine, insulin increased the cell survival only by 1.5-fold
regardless of azaserine treatment. Azaserine treatment also normalized
the ability of insulin to inactivate caspase-3 in cells incubated in 20 mM glucose (Fig. 2A) but not in cells exposed to
glucosamine (data not shown), further supporting the above
hypothesis.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 2.
Azaserine reverses the inhibitory effect of
high glucose but not glucosamine on the neuroprotective effect of
insulin. The contribution of the HBP to the high glucose-induced
attenuation of rescue effect of insulin was measured using a GFAT
inhibitor, azaserine. Following a 24-h pretreatment with 0.1 µM azaserine, R28 cells were deprived of serum with or
without 10 nM insulin for an additional 24 h. The
cells were immunostained with CM-1, an antibody recognizing activated
caspase-3 and counterstained with Hoechst dye. A, a
representative picture. Pictures of Hoechst staining and CM-1
immunostaining in each treatment condition were taken from identical
fields. Bar indicates 50 µm. B, the ability of
insulin to reduce apoptosis is expressed as a ratio of % pyknosis in
cells deprived of serum to that in cells deprived of serum and treated
with insulin. Data represent the mean ± S.E. of five randomly
sampled visual fields in n = 3 coverslips. The
experiments were repeated three times with reproducible results.
|
|
High Glucose and Glucosamine Increase UDP-HexNAc in R28
Cells--
To confirm whether high glucose or glucosamine leads to
increased levels of hexosamine metabolites in R28 cells and, if so, whether GFAT inhibition reverses this effect, intracellular UDP-HexNAc was measured after a 24-h incubation in 5 or 20 mM glucose
or 1.5 mM glucosamine, with or without insulin or 0.1 µM azaserine. In the absence of azaserine, the UDP-HexNAc
content in cells incubated in 5 mM glucose with insulin
decreased by 35% of control (5 mM glucose without insulin
and azaserine, 100% = 7.68 nmol/mg protein; p < 0.05), whereas 20 mM glucose treatment significantly
increased the content by 205.6 and 173.5% in the absence and presence
of insulin, respectively (Fig. 3). In the
presence of azaserine, on the other hand, the UDP-HexNAc content in
cells incubated in 5 mM glucose with insulin was
significantly lower than control (5 mM glucose without
insulin and with azaserine, 100% = 10.06 nmol/mg protein;
p < 0.05), whereas 20 mM glucose did not
increase the UDP-HexNAc content irrespective of the presence or absence of insulin. Azaserine alone had no effect on the absolute UDP-HexNAc content in cells incubated in 5 mM glucose
(p = 0.154). As expected, incubation in 1.5 mM glucosamine without azaserine increased the UDP-HexNAc
content by 1600 and 1800% in the absence and presence of insulin,
respectively. Azaserine did not reduce the UDP-HexNAc content in cells
irrespective of insulin treatment (Fig. 3). Thus, high glucose and
glucosamine increased the hexosamine end product, and GFAT inhibition
reversed the UDP-HexNAc content in cells incubated in high glucose but
not in low glucosamine. These data also suggest that insulin limits the
glucose flux through the HBP at normal glucose concentrations but not
when ambient glucose is elevated.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
High glucose and low glucosamine increase the
UDP-HexNAc content in R28 cells. R28 cells were incubated in 5 or
20 mM glucose or 1.5 mM glucosamine with or
without 10 nM insulin or 0.1 µM azaserine for
24 h. UDP-HexNAc, the end product of the HBP, was measured using
anion exchange high pressure liquid chromatography from perchloric acid
extracts of R28 cells and normalized to cells incubated in 5 mM glucose without insulin. (100% = 7.68 ± 1.16 and
10.06 ± 2.05 nmol/mg protein in the absence and presence of
azaserine, respectively.) Data represent the mean ± S.D.
(n = 3). *, §, and indicate p < 0.05, 0.001, and 0.0001 versus cells incubated in 5 mM glucose with the same azaserine treatment.
|
|
High Glucosamine, but Not High Glucose or Low Glucosamine, Reduces
IR Autophosphorylation--
To elucidate whether attenuation of
insulin action by high glucose and glucosamine occurs at the receptor
or at the post-receptor levels, the IR content and tyrosine
phosphorylation were quantified. R28 cells were exposed to the
indicated combinations of glucose, mannitol, or glucosamine for 24 h, followed by a 2-h serum depletion and a 5-min stimulation with 10 nM insulin. Immunoprecipitated IR was
phosphotyrosine-blotted and re-probed with IR antibody (Fig.
4, A and B). Whole
cell lysates were also blotted for IR (Fig. 4C).
Previously we demonstrated that at this concentration insulin
specifically activates IR and does not activate IGF-I receptor in R28
cells (9).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 4.
High glucosamine, but not high glucose or low
glucosamine, reduces IR autophosphorylation. Following a 24-h
incubation in the indicated media conditions and a 2-h serum
deprivation, R28 cells were stimulated with 10 nM insulin
for 5 min, and cell lysates were subjected to phosphotyrosine
(PY) blotting of immunoprecipitated IR (A),
re-probing with IR antibody (B), and IR blotting
(C). This experiment is representative of three independent
experiments (n = 3). IP,
immunoprecipitation; IB, immunoblotting; pro-IR,
pro-receptor.
|
|
Insulin stimulation substantially increased the phosphotyrosine content
of IR in cells incubated in control media and in those exposed to 20 mM glucose, 15 mM mannitol, or 1.5 mM glucosamine, whereas there was no detectable
phosphotyrosine in IR in cells exposed to 15 mM
glucosamine (Fig. 4A). IR content was similar among cells
treated with 5 mM glucose, 15 mM mannitol, and
20 mM glucose and slightly reduced in cells exposed to 1.5 mM glucosamine (Fig. 4B). Thus, when normalized
to total IR content, there was no difference in insulin-stimulated
IR tyrosine phosphorylation among cells incubated in control, mannitol,
high glucose, and low glucosamine media (n = 3, p = 0.34). In contrast, cells treated with 15 mM glucosamine expressed only a trace of IR (Fig.
4B). Thus, the lack of insulin stimulation of IR
autophosphorylation in cells exposed to 15 mM glucosamine
primarily resulted from reduced IR content.
As reported previously, R28 cells incubated in control media expressed
two isoforms of IR (125 and 115 kDa) (9), which were also observed
in cells exposed to 15 mM mannitol and 20 mM glucose (Fig. 4C). In comparison, cells treated with 1.5 and
15 mM glucosamine had an additional isoform of IR with a
lower molecular weight (Fig. 4C). On the other hand, both
IR and - blots detected a pro-receptor isoform with a molecular
mass of 220 kDa in cells treated with control, mannitol, and
high glucose media, whereas the electrophoretic mobility of the
pro-receptor was increased in a dose-dependent fashion in
cells exposed to glucosamine (Fig. 4, B and C).
In addition, the abnormally migrating pro-receptor content was also
increased in cells treated with 15 mM glucosamine. These
results suggest that glucosamine, in particular at higher concentration, may impair IR processing.
High Glucosamine Impairs Processing and Maturation of IR--
To
confirm whether high glucosamine treatment causes defective IR
processing, pulse-chase metabolic labeling was performed. R28 cells
were exposed to 15 mM mannitol or glucosamine for 8 h.
Following a 1-h incubation in methionine-free medium, the cells were
pulse-radiolabeled with [35S]methionine for 30 min and
then chased for the indicated periods. Immunoprecipitated IR was
subjected to 7.5% SDS-PAGE and fluorography (Fig.
5). The IR precursor was synthesized as a
single polypeptide chain and glycosylated with high mannose core
oligosaccharides in the endoplasmic reticulum. The ~190-kDa
pro-receptor was transported into the Golgi apparatus, where it
underwent proteolytic cleavage and oligosaccharide rearrangement to
generate the mature IR subunits (43-45). In cells incubated in 15 mM mannitol, one of the major bands at 220 kDa,
corresponding to the normal pro-receptor isoform (pro-IR in
Fig. 5), appeared at the start of chasing and reduced in content over
time. Mature IR and - subunits corresponding to 125- and 95-kDa
bands, respectively, appeared after 0.5 h of chase, increased in
content up to 3 h, and started to be reduced after 6 h. There
were additional bands with molecular masses of 245 and 105 kDa, both of
which could not be detected by immunoblotting with IR antibody (Fig.
4B). The latter is most likely IGF-IR that was
co-precipitated with the IR , because immunoblotting with the
specific antibody detected the IGF-IR subunit of 105 kDa in IR
immunoprecipitates (data not shown). Thus IR/IGF-I receptor hybrids are
expressed in R28 cells. In comparison, cells exposed to 15 mM glucosamine expressed neither mature IR nor -
throughout the entire chase periods (Fig. 5). The normal pro-receptor of 220 kDa was not apparent, whereas an alternative isoform of the
insulin pro-receptor of 160 kDa appeared, which was also detected by
immunoblotting with IR antibody (Fig. 4B). This
alternative form accumulated up to 1 h of chase and decreased
thereafter. Another band of 245 kDa was also observed in cells
incubated in 15 mM mannitol and could not be detected with
the IR immunoblotting. Therefore, high glucosamine treatment
inhibited normal processing and maturation of the IR and generated
alternative products of the pro-receptor.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 5.
Glucosamine impairs IR processing and
maturation. R28 cells were incubated in 15 mM mannitol
or 15 mM glucosamine for 8 h. The cells were exposed
to methionine-free medium for 1 h, followed by incubation in 200 µCi/ml [35S]methionine for 30 min. The cells were then
chased for the indicated periods. The cell lysates were
immunoprecipitated with IR antibody, followed by 7.5% SDS-PAGE and
fluorography. The data are representative of two independent
experiments (n = 2).
|
|
High Glucose and Low Glucosamine Do Not Impair Insulin Signaling to
PI3K in R28 Cells--
We reported previously (9) that insulin exerts
its neuroprotective effect mainly through the PI3K to Akt signaling
pathway in R28 cells. To elucidate post-receptor signaling steps where high glucose and low glucosamine perturb the insulin action, we evaluated insulin-stimulated IRS-1 phosphorylation and association of
IRS-1 with the p85 subunit of PI3K. Following identical treatments for
IR autophosphorylation analysis, R28 cells were harvested. Immunoprecipitated IRS-1 was subjected to phosphotyrosine and p85
blottings. As shown in Fig. 6, 5-min
insulin stimulation increased phosphotyrosine content of IRS-1 and p85
content co-immunoprecipitated with IRS-1 in cells exposed to 5 mM glucose, 15 mM mannitol, 20 mM
glucose, and 1.5 mM glucosamine (Fig. 6, B and
C). IRS-1 protein content was similar among all groups (Fig.
6A). Thus, when normalized to IRS-1 protein content, there
was no difference in tyrosine-phosphorylated IRS-1 content or in
IRS-1-associated p85 content among cells incubated in control,
mannitol, high glucose, and low glucosamine media (n = 3, p = 0.21).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 6.
High glucose and low glucosamine do not
impair IRS-1 phosphorylation and IRS-1/p85 association. Following
a 24-h incubation in the indicated media conditions and a 2-h serum
deprivation, R28 cells were stimulated with 10 nM insulin
for 5 min, and cell lysates were subjected to IRS-1 (A),
phosphotyrosine (PY) (B), and p85 blottings
(C). This experiment is representative of three independent
experiments (n = 3). IB,
immunoblotting.
|
|
High Glucose and Low Glucosamine Attenuate Insulin-stimulated
Phosphorylation of Akt--
Recent reports (18, 22-24, 28) suggested
that high glucose and glucosamine impair insulin-mediated Akt
activation in muscle tissues with no significant effect on signaling
cascades proximal to Akt. To test whether the inhibitory effect of high
glucose and low glucosamine on insulin-mediated anti-apoptosis in R28 cells was associated with the impaired insulin activation of Akt, insulin-stimulated phosphorylation of Akt was quantified. Following a
24-h incubation in the indicated combinations of glucose, mannitol, and
glucosamine, R28 cells were stimulated with 10 nM insulin for 30 min. Whole cell lysates were subjected to immunoblotting using
an antibody specifically recognizing Akt phosphorylated at
Ser473 and one recognizing total Akt (Fig.
7). Without insulin stimulation, Akt
phosphorylation was barely detected in any group. Although insulin
stimulation increased phospho-Akt content in all groups, cells
incubated in 20 mM glucose and in 1.5 mM
glucosamine had less phospho-Akt content compared with those incubated
in 5 mM glucose or 15 mM mannitol. The total
Akt content was similar in all treatment conditions. Thus, when
normalized to total protein content, the ratio of phospho- to total Akt
content after insulin stimulation was reduced to ~75% of the
controls in cells exposed to 20 mM glucose or 1.5 mM glucosamine (Fig. 7, without azaserine, p < 0.01). Next, to test whether the increased flux of
glucose through the HBP was involved in the reduced insulin activation of Akt, 0.1 µM azaserine was added to the media 24 h
prior to insulin stimulation. Insulin-stimulated Akt phosphorylation
was increased to the control level in cells exposed to 20 mM glucose and azaserine but was not restored in cells
exposed to 1.5 mM glucosamine (Fig. 7, with azaserine).
Thus, blocking glucose entry into the HBP reversed the high
glucose-induced attenuation of Akt phosphorylation after insulin
stimulation.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 7.
High glucose and low glucosamine attenuate
insulin stimulation of Akt phosphorylation in R28 cells. Following
a 24-h incubation in the indicated media conditions with or without 0.1 µM azaserine and a 2-h serum deprivation, R28 cells were
stimulated with 10 nM insulin for 30 min, and cell lysates
were subjected to phospho-Akt (Ser-473) or total Akt immunoblotting
(A). B, quantification of relative ratio of
phospho- to total Akt content after insulin stimulation, expressed as
the percentage relative to 5 mM glucose treatment. Each
bar represents the mean ± S.E. (n = 4). * indicates p < 0.01 versus cells
incubated in 5 mM glucose and correspondingly
treated.
|
|
High Glucose and Glucosamine Do Not Alter Intracellular ATP
Content--
A previous report (46) suggested that intracellular ATP
depletion was the major cause of glucosamine-induced insulin resistance in fat cells. To test whether glucosamine reduced ATP content in R28
cells, ATP was measured enzymatically using hexokinase and
glucose-6-phosphate dehydrogenase 24 h after incubation in the
indicated media conditions. As shown in Fig.
8, ATP content was not significantly
different among cells exposed to 5 mM glucose, 15 mM mannitol, 20 mM glucose, and 1.5 mM glucosamine regardless of insulin stimulation. Cells
incubated in 15 mM glucosamine tended to have less ATP
content, but the value did not reach statistical significance.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 8.
High glucose and glucosamine do not
significantly decrease intracellular ATP content in R28 cells. R28
cells were incubated in the indicated media conditions for 24 h.
ATP content was then measured fluorometrically from perchloric acid
extracts. Data represent the mean ± S.D. (n = 3).
|
|
Glucosamine Alters IR Processing but Does Not Induce Apoptosis
in L6 Cells--
To test whether glucosamine induces aberrant IR
processing and apoptosis in other insulin-sensitive cells, L6 cells
were treated as described above. IR and - immunoblots
demonstrated that glucosamine reduced the mature and subunits
and increased the abnormally migrating pro-receptor isoform in a
dose-dependent manner in L6 cells, similar to R28 cells.
However, glucosamine did not lead to apoptosis in L6 cells even at the
15 mM concentration (Fig. 9).
Thus, glucosamine-induced apoptosis in R28 cells was a cell type-specific event.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 9.
Glucosamine affects IR processing but does
not induce apoptosis in L6 cells. Following a 24-h incubation in
the indicated media conditions, L6 cell lysates were subjected to IR
(A) or IR immunoblotting (B). C,
R28 cells and L6 cells were incubated in the indicated concentrations
of glucosamine for 24 h, followed by Hoechst staining to determine
% pyknosis. Data represent the mean ± S.E. of five randomly
sampled visual fields in n = 3 coverslips. The
experiments were repeated three times with reproducible results.
|
|
 |
DISCUSSION |
The present study demonstrated the following findings. 1) High
glucose and relatively low concentrations of glucosamine inhibited the
ability of insulin to rescue R28 cells, a model of retinal neurons,
from apoptosis induced by serum deprivation. 2) The two conditions
elevated UDP-HexNAc, the end product of the HBP, in R28 cells. 3) High
glucose and glucosamine attenuated Akt phosphorylation after insulin
stimulation with no effect on IR autophosphorylation, IRS-1
phosphorylation, and IRS-1/p85 association. 4) These three events were
independent of an osmotic stress, because mannitol treatment did not
have similar effects. 5) The amidotransferase inhibitor, azaserine,
which inhibits GFAT, reversed the above events in cells exposed to high
glucose but not to glucosamine, which enters into the HBP distal to
GFAT. These lines of evidence strongly suggest that high glucose
impairs insulin action as a neurotrophic factor in R28 cells, at least
in part, via the excessive flux of glucose through the HBP.
In the present study, 20 mM glucose elevated the UDP-HexNAc
content ~2-fold in R28 cells. Previously, we showed (20) that in
3T3-L1 adipocytes, high glucose had a much smaller effect on UDP-HexNAc
concentrations, since an 18-h incubation in 25 mM glucose plus 0.6 nM insulin led to only a 30% increase in the
UDP-HexNAc content. However, other studies demonstrated that high
glucose treatment elevated the nucleotide sugar 2-fold in porcine
glomerular mesangial cells and rat-1 fibroblasts (47, 48). An in
vivo study indicated that hyperglycemia increased the
UDP-HexNAc:UDP-hexose ratio in muscle and to a much lesser extent in
liver in rats (41). Thus, the degree to which high glucose increases
intracellular UDP-HexNAc depends on the cell type. Interestingly,
incubation in 1.5 mM glucosamine increased the hexosamine
end product over 15-fold in R28 cells. In a previous report (47)
incubation with 7 mM glucosamine gave rise to at most a
4-fold increase in UDP-HexNAc in mesangial cells. However, incubation
of 3T3-L1 cells with 0.5 mM glucosamine in the presence of
0.6 nM insulin and 5 mM glucose increased
intracellular UDP-HexNAc concentrations ~10-fold. Higher glucosamine
concentrations caused no further increase, suggesting limitation of
UDP-HexNAc synthesis at one of two steps beyond hexokinase (20). The
present data in R28 cells are consistent with a relatively high
capacity HBP, which may contribute to the susceptibility of retinal
neurons to apoptosis.
The impaired insulin activation of Akt without perturbation of the
proximal signaling events after exposure to high glucose and/or
glucosamine was previously demonstrated in several types of cells and
tissues. Heart et al. (18) showed that exposure of 3T3-L1
adipocytes to 50 mM glucosamine for 6 h attenuated
insulin stimulation of Akt activity by 50% with no change in the
phosphorylation of IR and IRS-1/2 and with minimal reduction of PI3K
activity. In isolated muscles, glucosamine did not alter IR number and
IR tyrosine kinase activity (15), and high glucose impaired Akt activation by insulin with PI3K activity being unaffected (22, 23).
Similar observations were also reported in Zucker diabetic fatty liver,
although the role of the HBP was not investigated (24). However, in
other reports (16, 17, 28) exposure to high glucose or glucosamine
affected post-receptor insulin signaling steps proximal to Akt. Singh
et al. (28) presented evidence that in rat-1 fibroblasts, 20 mM glucose or 1 mM glucose plus 3 mM glucosamine treatment led to insulin resistance for glycogen synthase activity, which was associated with a reduced ability
of insulin to activate PI3K and Akt. In vivo glucosamine infusion studies showed reduced IRS-1 phosphorylation and PI3K activity
(16, 17). Although the PI3K activity was not measured in the current
study, neither high glucose nor low glucosamine treatment perturbed the
insulin signaling cascades proximal to the PI3K. Thus, the steps at
which high glucose and glucosamine perturb insulin signaling may also
depend on cell and tissue types.
No matter which signaling step is initially altered by exposure to high
glucose, of importance is that the reduced ability of insulin to
stimulate Akt likely renders retinal neurons vulnerable to
pro-apoptotic stresses, because insulin exerts its anti-apoptotic effect on neuronal cells, at least in part, through the PI3K/Akt pathway (9, 49). In eyes with diabetic retinopathy, multiple pro-apoptotic factors are induced including oxidative stress, ischemia,
and altered glutamate metabolism (50). Therefore, if the current
in vitro observations apply to the retina in
vivo, hyperglycemia and subsequent activation of the HBP could
direct retinal neurons to cell death by impairing the neuroprotective effect of insulin. A 2-fold increase in UDP-HexNAc induced by exposure
to high glucose had a similar impact on the attenuation of the ability
of insulin to rescue R28 cells from apoptosis and stimulate Akt as the
15-fold increase in the nucleotide sugar caused by 1.5 mM
glucosamine treatment. Thus, even a modest increase in glucose flux via
HBP may have a critical effect on the function and survival of retinal
neurons. Exposure to high glucose may induce several intracellular
events, which act synergistically with products of HBP to block the
anti-apoptotic effect of insulin.
The mechanism by which excessive glucose flux through HBP attenuates
insulin-stimulated Akt activity is still unclear. Because UDP-HexNAc
serves as a substrate for glycosylation of proteins and lipids
(12-14), it is conceivable that glycosylation of Akt, possibly via
O-linked N-acetylglucosamine modification on
Ser/Thr residues (51), may be directly affected. Alternatively,
hexosamines might regulate the activities of other protein kinases
and/or phosphatases.
Another intriguing observation in the present study is that glucosamine
at higher concentrations not only inhibited the neuroprotective action
of insulin but also induced apoptosis in R28 cells. This glucosamine-induced apoptosis was cell type-specific, because L6 cells
were resistant to high glucosamine treatment in the present and in
previous studies (52, 53). There are a few possibilities to explain
this cytotoxic effect of glucosamine on retinal neurons. The first is
the inhibition of N-glycosylation of critical proteins. Tunicamycin, a well known inhibitor of N-linked
glycosylation (54), specifically induces apoptotic cell death in
neurons such as sympathetic neurons and cerebellar granule cells but
not in differentiated PC 12 cells (55, 56), whereas tunicamycin exerts a pro-survival effect in non-neural cells; it can block tumor necrosis
factor -induced apoptosis in hepatocytes (57). Glucosamine, but not
other amino sugars such as galactosamine and mannosamine, is also known
to inhibit N-glycosylation (54). The defective processing of
IR in cells exposed to 15 mM glucosamine in the present
study is consistent with previous work (15) in rat-1 fibroblasts
overexpressing the human IR. It likely reflects an overall impairment
of N-linked glycosylation, because the processing of the
IGF-I receptor was also
impaired.2 Protein
glycosylation is required for neurite elongation, membrane transport of
nutrients, and axonal transport (58). Specific alterations in
glycosylation of N-linked glycoproteins such as IR and
IGF-IR may, therefore, be endogenous signals for the induction of
apoptosis in neuronal cells, because glucosamine also affected IR
processing in L6 cells with no induction of apoptosis. On the other
hand, previous papers (59, 60) indicated that glucosamine as well as
tunicamycin preferentially kill tumorigenic cells rather than
nontumorigenic cells. Therefore, inhibition of
N-glycosylation may have induced apoptosis in R28 cells in
part because they are immortalized cells.
Alternatively, glucosamine may inhibit the activity of specific enzymes
regulating glycolysis (61). Because the retina highly depends on
glycolysis as an energy source, blockade of ATP production from
glycolysis would compromise neuronal survival in the retina. Hersko
et al. (46) pointed out that ATP depletion might be a mechanism by which glucosamine blocks insulin signaling to glucose transport in 3T3-L1 adipocytes. This seems unlikely, however, in our
model, because ATP concentrations were not significantly reduced in R28
cells exposed even to 15 mM glucosamine. Furthermore, a
recent report (62) presented evidence against the role of ATP depletion
in causing glucosamine on insulin resistance in 3T3-L1 adipocytes.
The third possibility is that accumulated UDP-HexNAc may alter the
function of critical proteins regulating neuronal viability and
functions by O-linked N-acetylglucosamine
modification (51). The O-linked glycosylation on serine and
threonine residues with N-acetylglucosamine moiety is an
important regulatory modification that may have a reciprocal
relationship with O-phosphorylation and modulate many
biological events in eukaryotes (51).
In vivo, flux through the HBP is highly regulated, in part
via allosteric feedback inhibition of GFAT by
UDP-N-acetylglucosamine. Because the pro-apoptotic effect in
serum-fed R28 cells was only seen after exposure to glucosamine and not
after exposure to high glucose, and the former but not the latter
caused massive accumulation of UDP-HexNAc, it is not clear whether this
effect of glucosamine is pharmacological or possibly has its
counterpart in the diabetic milieu in the retina. Prolonged exposure to
high glucose milieu may cause neuronal cell death. Unfortunately, we
could not address this issue in our experimental paradigm, because
prolonged culture itself, independently of glucose concentrations,
caused confluency-induced apoptosis in R28 cells (data not shown).
However, if this was the case, the activated HBP per se may
trigger apoptotic death of neurons in DR independently of impaired
insulin action.
In summary, the present study suggests that excessive glucose flux
through the HBP may direct retinal neurons to apoptosis in a
bimodal fashion, i.e. via perturbation of insulin action to
promote survival, at least in part, mediated by Akt and via induction
of apoptosis possibly by altered glycosylation of proteins that
maintain cell survival. Diabetes may cause retinal neurodegeneration by
the excessive entry of glucose into the HBP.
 |
ACKNOWLEDGEMENTS |
We thank Ellen B. Wolpert for technical
expertise and help in preparation of the manuscript. We also thank
Baiyang Xu for assistance in measuring ATP content.
 |
FOOTNOTES |
*
This work was supported by the Pennsylvania Lions Sight
Conservation and Eye Research Foundation (to M. N.), National
Institutes of Health Grants EY12021 (to T. W. G.) and DK02001 (to
M. G. B.), Juvenile Diabetes Research Foundation (to T. W. G.,
D. A. A., and K. F. L), American Diabetes Association (to
T. W. G.), Research to Prevent Blindness, and Jack and Nancy
Turner, Athens, GA.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Ulerich
Ophthalmology Research Center, Dept. of Ophthalmology, H166,
Pennsylvania State University College of Medicine, 500 University Dr.,
Hershey, PA 17033. Tel.: 717-531-5542; Fax: 717-531-7667; E-mail:
tgardner@psu.edu.
Published, JBC Papers in Press, September 17, 2001, DOI 10.1074/jbc.M108594200
2
M. Nakamura and T. W. Gardner, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
DR, diabetic
retinopathy;
HBP, hexosamine biosynthetic pathway;
IR, insulin
receptor;
IRS, insulin receptor substrate;
IGF-I, insulin-like growth
factor-I;
PI3K, phosphoinositide 3-kinase;
GFAT, glutamine:fructose-6-phosphate amidotransferase;
DMEM, Dulbecco's
modified Eagle's medium;
UDP-HexNAc, UDP-N-acetylhexosamines;
MOPS, 4-morpholinepropanesulfonic
acid;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Hammes, H. P.,
Federoff, H. J.,
and Brownlee, M.
(1995)
Mol. Med.
1,
527-534[Medline]
[Order article via Infotrieve]
|
| 2.
|
Barber, A. J.,
Lieth, E.,
Khin, S. A.,
Antonetti, D. A.,
Buchanan, A. G.,
and Gardner, T. W.
(1998)
J. Clin. Invest.
102,
783-791[Medline]
[Order article via Infotrieve]
|
| 3.
|
Podesta, F.,
Romeo, G.,
Liu, W.-H.,
Krajewski, S.,
Reed, J. C.,
Gerhardinger, C.,
and Lorenzi, M.
(2000)
Am. J. Pathol.
156,
1025-1032[Abstract/Free Full Text]
|
| 4.
|
Huck, S.
(1983)
Brain. Res. Bull.
10,
667-674[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Meyer-Franke, A.,
Kaplan, M. R.,
Pfrieger, F. W.,
and Barres, B. A.
(1995)
Neuron
15,
805-819[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Seigel, G. M.
(1996)
In Vitro Cell. Dev. Biol.
32,
66-68
|
| 7.
|
Tezel, G.,
and Wax, M.
(1999)
Investig. Ophthal. & Vis. Sci.
40,
2660-2667
|
| 8.
|
Seigel, G. M.,
Chiu, L.,
and Paxhia, A.
(2000)
Mol. Vis.
6,
21
|
| 9.
|
Barber, A. J.,
Nakamura, M.,
Wolpert, E. B.,
Reiter, C. E. N.,
Seigel, G. M.,
Antonetti, D. A.,
and Gardner, T. W.
(2001)
J. Biol. Chem.
276,
32814-32821[Abstract/Free Full Text]
|
| 10.
|
Naeser, P.
(1997)
Upsala J. Med. Sci.
102,
35-40[Medline]
[Order article via Infotrieve]
|
| 11.
|
Rodrigues, M.,
Waldbillig, R. J.,
Rajagopalan, S.,
Hackett, J.,
LeRoith, D.,
and Chader, G. J.
(1988)
Brain Res.
443,
389-394[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Marshall, S.,
Bacote, V.,
and Traxinger, R. R.
(1991)
J. Biol. Chem.
266,
4706-4712[Abstract/Free Full Text]
|
| 13.
|
McClain, D. A.,
and Crook, E. D.
(1996)
Diabetes
45,
1003-1009[Abstract]
|
| 14.
|
Rosetti, L.
(2000)
Endocrinology
141,
1922-1925[Free Full Text]
|
| 15.
|
Robinson, K. A.,
Sens, D. A.,
and Buse, M. G.
(1993)
Diabetes
42,
1333-1346[Abstract]
|
| 16.
|
Hawkins, M.,
Hu, M., Yu, J.,
Eder, H.,
Vuguin, P.,
She, L.,
Barzilai, N.,
Leiser, M.,
Backer, J. M.,
and Rossetti, L.
(1999)
J. Biol. Chem.
274,
31312-31319[Abstract/Free Full Text]
|
| 17.
|
Kim, Y.-B.,
Zhu, J.-S.,
Zierath, J. R.,
Shen, H.-Q.,
Baron, A. D.,
and Kahn, B. B.
(1999)
Diabetes
48,
310-320[Abstract]
|
| 18.
|
Heart, E.,
Choi, W. S.,
and Sung, C. K.
(2000)
Am. J. Physiol.
278,
E103-E112[Abstract/Free Full Text]
|
| 19.
|
Ross, S. T.,
Chen, X.,
Hope, H. R.,
Sun, S.,
McMahon, E. G.,
Broschat, K.,
and Gulve, E. A.
(2000)
Biochem. Biophys. Res. Commun.
273,
1033-1041[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Nelson, B. A.,
Robinson, K. A.,
and Buse, M. G.
(2000)
Diabetes
49,
981-991[Abstract]
|
| 21.
|
Krook, A.,
Roth, R. A.,
Jiang, X. J.,
Zierath, J. R.,
and Wallberg-Henriksson, H.
(1998)
Diabetes
47,
1281-1286[Abstract]
|
| 22.
|
Kurowski, T. G.,
Lin, Y.,
Luo, Z.,
Tsichlis, P. N.,
Buse, M. G.,
and Heydrick, S. J.
(1999)
Diabetes
48,
658-663[Abstract]
|
| 23.
|
Song, X. M.,
Kawano, Y.,
Krook, A.,
Ryder, J. W.,
Efendic, S.,
Roth, R. A.,
Wallberg-Henriksson, H.,
and Zierath, J. R.
(1999)
Diabetes
48,
664-670[Abstract]
|
| 24.
|
Nawano, M.,
Ueta, K.,
Arakawa, K.,
Saito, A.,
Funaki, M.,
Anai, M.,
Kikuchi, M.,
Oka, Y.,
and Asano, T.
(1999)
Biochem. Biophys. Res. Commun.
266,
252-256[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
James, L. R.,
Fantus, I. G.,
Goldberg, H.,
Ly, H.,
and Scholey, J. W.
(2000)
Am. J. Physiol.
279,
F718-F727
|
| 26.
|
Singh, L. P.,
and Crook, E. D.
(2000)
Am. J. Physiol.
279,
F646-F654
|
| 27.
|
Kornfeld, R.
(1964)
J. Biol. Chem.
242,
3135-3141[Abstract/Free Full Text]
|
| 28.
|
Singh, L. P.,
Gennerette, D.,
Simmons, S.,
and Crook, E. D.
(2001)
J. Diabetes Compl.
15,
88-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Kumagai, A. K.
(1999)
Diabetes Metab. Rev.
15,
261-273
|
| 30.
|
Giardino, I.,
Fard, A. K.,
Hatchell, D. L.,
and Brownlee, M.
(1998)
Diabetes
47,
1114-1120[Abstract]
|
| 31.
|
Rungger-Brändle, E.,
Dosso, A. A.,
and Leuenberger, P. M.
(2000)
Investig. Ophthalmol. & Vis. Sci.
41,
1971-1980[Abstract/Free Full Text]
|
| 32.
|
Barber, A. J.,
Antonetti, D. A.,
Gardner, T. W.,
and the Penn State Retina Research Group.
(2000)
Investig. Ophthalmol. & Vis. Sci.
41,
3561-3568[Abstract/Free Full Text]
|
| 33.
|
Antonetti, D. A.,
Barber, A. J.,
Hollinger, L. A.,
Wolpert, E. B.,
and Gardner, T. W.
(1999)
J. Biol. Chem.
274,
23463-23467[Abstract/Free Full Text]
|
| 34.
|
Heath, H.,
Kang, S. S.,
and Philippou, D.
(1975)
Diabetologia
11,
57-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Tang, J.,
Zhu, X. W.,
Lust, W. D.,
and Kern, T. S.
(2000)
Diabetologia
43,
1417-1423[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Mazlen, R. G.,
Muellenberg, C. G.,
and O'Brien, P. J.
(1970)
Exp. Eye Res.
9,
1-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Tesoriere, G.,
Vento, R.,
Magistro, D.,
and Dones, F.
(1971)
Eur. J. Biochem.
19,
289-293[Medline]
[Order article via Infotrieve]
|
| 38.
|
Heath, H.,
Patterson, R. A.,
and Hart, J. C. D.
(1967)
Diabetologia
3,
515-518[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Walker, F.,
and Patrick, R. S.
(1968)
Diabetes
17,
105-107[Medline]
[Order article via Infotrieve]
|
| 40.
|
Yaffe, D.
(1968)
Proc. Natl. Acad. Sci. U. S. A.
61,
477-483[Free Full Text]
|
| 41.
|
Robinson, K. A.,
Weinstein, M. L.,
Lindenmayer, G. E.,
and Buse, M. G.
(1995)
Diabetes
44,
1438-1446[Abstract]
|
| 42.
| Passonneau, J. V., and Lowry, O. H. (1993)
Enzymatic Analysis: A Practical Guide, pp. 10-11, 122-123,
Humana Press Inc., Totowa, NJ
|
| 43.
|
Hedo, J. A.,
Kahn, C. R.,
Hayashi, M.,
Yamada, K. M.,
and Kasuga, M.
(1983)
J. Biol. Chem.
258,
10020-10026[Abstract/Free Full Text]
|
| 44.
|
Lane, M. D.,
Ronnet, G.,
Slieker, L. J.,
Kohanski, R. A.,
and Olson, T. L.
(1985)
Biochimie (Paris)
67,
1069-1080[Medline]
[Order article via Infotrieve]
|
| 45.
|
Gorden, P.,
Arakaki, R.,
Collier, E.,
and Carpentier, J-L.
(1989)
Yale J. Biol. Med.
62,
521-531[Medline]
[Order article via Infotrieve]
|
| 46.
|
Hersko, R.,
Heimberg, M.,
Chi, M.,
and Mueckler, M.
(1998)
J. Biol. Chem.
273,
20658-20668[Abstract/Free Full Text]
|
| 47.
|
Kolm-Litty, V.,
Sauer, U.,
Nerlich, A.,
Lehmann, R.,
and Schleicher, E. D.
(1998)
J. Clin. Invest.
101,
160-169[Medline]
[Order article via Infotrieve]
|
| 48.
|
Crook, E. D.,
Crenshaw, G.,
Veerababu, G.,
and Singh, L. P.
(2000)
Endocrinology
141,
1962-1970[Abstract/Free Full Text]
|
| 49.
|
Dudek, H.,
Datta, S. R.,
Franke, T. F.,
Birnbaum, M. J.,
Yao, R.,
Cooper, G. M.,
Segal, R. A.,
Kaplan, D. R.,
and Greenberg, M. E.
(1997)
Science
275,
661-665[Abstract/Free Full Text]
|
| 50.
|
Gardner, T. W.,
Antonetti, D. A.,
Barber, A. J.,
LaNoue, K. F.,
and Nakamura, M.
(2000)
Diabetes Technol. Therap.
2,
601-608[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Hart, G. W.
(1997)
Annu. Rev. Biochem.
66,
315-335[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Maher, F.,
and Harrison, L. C.
(1991)
Biochim. Biophys. Acta
1089,
27-32[Medline]
[Order article via Infotrieve]
|
| 53.
|
Davidson, M. B.,
Hunt, K.,
and Fernandez-Mejia, C.
(1994)
Biochim. Biophys. Acta
1201,
113-117[Medline]
[Order article via Infotrieve]
|
| 54.
|
Elbein, A. D.
(1987)
Annu. Rev. Biochem.
56,
497-534[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Tolkovsky, A. M.
(1987)
J. Neurosci.
7,
110-119[Abstract]
|
| 56.
|
Chang, J. Y.,
Korolev, V.,
and Wang, J.-Z.
(1997)
Neurotoxicology
18,
129-136[Medline]
[Order article via Infotrieve]
|
| 57.
|
Leist, M.,
and Wendel, A.
(1995)
Eur. J. Pharmacol.
292,
201-204[Medline]
[Order article via Infotrieve]
|
| 58.
|
Heacock, A. M.
(1982)
Brain Res.
241,
307-315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Bekesi, J. G.,
Bekesi, E.,
and Winzler, R. J.
(1969)
J. Biol. Chem.
244,
3766-3772[Abstract/Free Full Text]
|
| 60.
|
Tesoriere, G.,
Tesoriere, L.,
Vento, R.,
Giuliano, M.,
and Cantoro, G.
(1984)
Experientia (Basel)
40,
705-707
|
| 61.
|
Tesoriere, G.,
Vento, R.,
and Calvaruso, G.
(1975)
Biochim. Biophys. Acta
385,
58-67[Medline]
[Order article via Infotrieve]
|
| 62.
|
Kang, J.,
Heart, E.,
and Sung, C. K.
(2001)
Am. J. Physiol.
280,
E428-E435[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. W. van Dijk, P. H. B. Kok, M. Garvin, M. Sonka, J. H. DeVries, R. P. J. Michels, M. E. J. van Velthoven, R. O. Schlingemann, F. D. Verbraak, and M. D. Abramoff
Selective Loss of Inner Retinal Layer Thickness in Type 1 Diabetic Patients with Minimal Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci.,
July 1, 2009;
50(7):
3404 - 3409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Luo, Y. Soesanto, and D. A. McClain
Protein Modification by O-Linked GlcNAc Reduces Angiogenesis by Inhibiting Akt Activity in Endothelial Cells
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2008;
28(4):
651 - 657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Fox, X. Han, S. Kelly, A. H. Merrill Jr., R. E. Martin, R. E. Anderson, T. W. Gardner, and M. Kester
Diabetes Alters Sphingolipid Metabolism in the Retina: A Potential Mechanism of Cell Death in Diabetic Retinopathy
Diabetes,
December 1, 2006;
55(12):
3573 - 3580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Antonetti, A. J. Barber, S. K. Bronson, W. M. Freeman, T. W. Gardner, L. S. Jefferson, M. Kester, S. R. Kimball, J. K. Krady, K. F. LaNoue, et al.
Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease
Diabetes,
September 1, 2006;
55(9):
2401 - 2411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Ola, D. A. Berkich, Y. Xu, M. T. King, T. W. Gardner, I. Simpson, and K. F. LaNoue
Analysis of glucose metabolism in diabetic rat retinas
Am J Physiol Endocrinol Metab,
June 1, 2006;
290(6):
E1057 - E1067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E.N. Reiter, X. Wu, L. Sandirasegarane, M. Nakamura, K. A. Gilbert, R. S.J. Singh, P. E. Fort, D. A. Antonetti, and T. W. Gardner
Diabetes reduces Basal retinal insulin receptor signaling: reversal with systemic and local insulin.
Diabetes,
April 1, 2006;
55(4):
1148 - 1156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Kniep, C. Roehlecke, N. Ozkucur, A. Steinberg, F. Reber, L. Knels, and R. H. W. Funk
Inhibition of Apoptosis and Reduction of Intracellular pH Decrease in Retinal Neural Cell Cultures by a Blocker of Carbonic Anhydrase.
Invest. Ophthalmol. Vis. Sci.,
March 1, 2006;
47(3):
1185 - 1192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Cooksey, S. Pusuluri, M. Hazel, and D. A. McClain
Hexosamines regulate sensitivity of glucose-stimulated insulin secretion in {beta}-cells
Am J Physiol Endocrinol Metab,
February 1, 2006;
290(2):
E334 - E340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhou, B. K. Deo, K. Hosoya, T. Terasaki, I. G. Obrosova, F. C. Brosius III, and A. K. Kumagai
Increased JNK Phosphorylation and Oxidative Stress in Response to Increased Glucose Flux through Increased GLUT1 Expression in Rat Retinal Endothelial Cells
Invest. Ophthalmol. Vis. Sci.,
September 1, 2005;
46(9):
3403 - 3410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Cacicedo, S. Benjachareowong, E. Chou, N. B. Ruderman, and Y. Ido
Palmitate-Induced Apoptosis in Cultured Bovine Retinal Pericytes: Roles of NAD(P)H Oxidase, Oxidant Stress, and Ceramide
Diabetes,
June 1, 2005;
54(6):
1838 - 1845.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Tian, K. G. T. Hagen, L. Shum, H. C. Hang, Y. Imbert, W. W. Young Jr, C. R. Bertozzi, and L. A. Tabak
An Inhibitor of O-Glycosylation Induces Apoptosis in NIH3T3 Cells and Developing Mouse Embryonic Mandibular Tissues
J. Biol. Chem.,
November 26, 2004;
279(48):
50382 - 50390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Seki, T. Tanaka, H. Nawa, T. Usui, T. Fukuchi, K. Ikeda, H. Abe, and N. Takei
Involvement of Brain-Derived Neurotrophic Factor in Early Retinal Neuropathy of Streptozotocin-Induced Diabetes in Rats: Therapeutic Potential of Brain-Derived Neurotrophic Factor for Dopaminergic Amacrine Cells
Diabetes,
September 1, 2004;
53(9):
2412 - 2419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Yu, R. V. S. Rajala, J. F. McGinnis, F. Li, R. E. Anderson, X. Yan, S. Li, R. V. Elias, R. R. Knapp, X. Zhou, et al.
Involvement of Insulin/Phosphoinositide 3-Kinase/Akt Signal Pathway in 17{beta}-Estradiol-mediated Neuroprotection
J. Biol. Chem.,
March 26, 2004;
279(13):
13086 - 13094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wu, C. E. N. Reiter, D. A. Antonetti, S. R. Kimball, L. S. Jefferson, and T. W. Gardner
Insulin Promotes Rat Retinal Neuronal Cell Survival in a p70S6K-dependent Manner
J. Biol. Chem.,
March 5, 2004;
279(10):
9167 - 9175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. N. Reiter, L. Sandirasegarane, E. B. Wolpert, M. Klinger, I. A. Simpson, A. J. Barber, D. A. Antonetti, M. Kester, and T. W. Gardner
Characterization of insulin signaling in rat retina in vivo and ex vivo
Am J Physiol Endocrinol Metab,
October 1, 2003;
285(4):
E763 - E774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Assa-Kunik, D. Fishman, S. Kellman-Pressman, S. Tsory, S. Elhyany, O. Baharir, and S. Segal
Alterations in the Expression of MHC Class I Glycoproteins by B16BL6 Melanoma Cells Modulate Insulin Receptor-Regulated Signal Transduction and Augments Resistance to Apoptosis
J. Immunol.,
September 15, 2003;
171(6):
2945 - 2952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Pang, D. L. Hunton, P. Bounelis, and R. B. Marchase
Hyperglycemia Inhibits Capacitative Calcium Entry and Hypertrophy in Neonatal Cardiomyocytes
Diabetes,
December 1, 2002;
51(12):
3461 - 3467.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Vosseller, L. Wells, M. D. Lane, and G. W. Hart
Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes
PNAS,
April 16, 2002;
99(8):
5313 - 5318.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|